BC Extra | May 23, 2017
Financial News

Lapam leads Canbridge's $25M series B

Canbridge Life Sciences Ltd. (Beijing, China) raised $25 million in a series B led by Lapam Capital. Also participating were Qiming Venture Partners, Yuanming Capital, Yanyuan Capital, Biossom Investment Management and WuXi AppTec Co. Ltd....
BC Week In Review | Aug 22, 2016
Company News

Boehringer Ingelheim, Canbridge deal

Boehringer will manufacture Canbridge’s AV-203 ( CAN-017 ) in Shanghai. AV-203, an Erb-b2 receptor tyrosine kinase 3 ( ERBB3 ; HER3 ; EGFR3 )-targeted antibody, completed Phase I testing to treat solid tumors. Earlier this year, Aveo Pharmaceuticals...
BC Extra | Aug 12, 2016
Company News

Boehringer to manufacture Canbridge's ESCC candidate

Canbridge Life Sciences Ltd. (Beijing, China) said Boehringer Ingelheim GmbH (Ingelheim, Germany) will manufacture AV-203 ( CAN-017 ), Canbridge's candidate to treat esophageal squamous cell cancer, in Shanghai. Canbridge plans to begin a Phase IIa trial...
BioCentury | Mar 28, 2016

Canbridge can-can

Canbridge Life Sciences Ltd .'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its...
BC Week In Review | Mar 28, 2016
Company News

Aveo Pharmaceuticals, Canbridge deal

Aveo granted Canbridge exclusive, ex-North American rights to oncology candidate AV-203 . Aveo will receive $1 million up front and is eligible for $133 million in milestones, plus tiered, low double-digit royalties. Canbridge said it plans...
BC Extra | Mar 22, 2016
Company News

Canbridge in-licenses Aveo mAb

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) granted Canbridge Life Sciences Ltd. (Beijing, China) exclusive, ex-North American rights to oncology candidate AV-203 . Aveo will receive $1 million up front and is eligible for $133 million in milestones, plus...
BC Innovations | Sep 10, 2015
Emerging Company Profile

Epitope as prologue

Most antibody platforms target specific antigens, but offer little control over the exact binding location on the target or how the antibody affects activity. Hummingbird Bioscience Pte. Ltd. has developed a system for pinpointing the...
BioCentury | Apr 6, 2015

Up, up and acquired

For the first time since 1Q14, none of the biotech market cap segments fell. While the $200-$499 million tier treaded water, all other segments finished in the black, led by the $1-$4.9 billion segment. Large...
BC Week In Review | Jan 19, 2015
Company News

Aveo Pharmaceuticals cancer news

Aveo eliminated its internal research function and reduced headcount by 40 (67%) to 20 to focus resources on advancing its clinical pipeline. The cuts include CSO Jeno Gyuris and are expected to reduce compensation expenses...
BC Week In Review | Jun 23, 2014
Clinical News

AV-203: Phase I data

An open-label, U.S. Phase I trial in 22 patients with metastatic or advanced solid tumors showed that 2, 5, 9, 14 and 20 mg/kg doses of IV AV-203 every 2 weeks led to 8 cases...
Items per page:
1 - 10 of 16